Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Doris C. Brooker is active.

Publication


Featured researches published by Doris C. Brooker.


Obstetrics & Gynecology | 2004

Hysteroscopy and cytology in endometrial cancer.

William H. Bradley; Matthew P. Boente; Doris C. Brooker; Peter A. Argenta; Levi S. Downs; Patricia L. Judson; Linda F. Carson

OBJECTIVE: To estimate the effect of preoperative diagnostic hysteroscopy on peritoneal cytology in patients with endometrial cancer. METHODS: A total of 256 charts were reviewed. Two cohorts were established based on diagnosis by hysteroscopy or blind endometrial sampling via either endometrial biopsy or dilatation and curettage (D&C). Malignant or suspicious peritoneal cytology was the primary outcome. Cohorts were compared using logistic regression to correct for potential confounders of stage and grade. RESULTS: A total of 204 cases were diagnosed by endometrial biopsy or D&C, whereas 52 were identified by hysteroscopy. In the endometrial biopsy or D&C arm, 14 of 204 (6.9%) patients had malignant or suspicious cytology compared with 7 of 52 (13.5%) patients in the hysteroscopy arm (P = .15). After logistic regression controlling for stage and grade, the odds ratio for positive cytology after hysteroscopy was 3.88 (95% confidence interval 1.11,13.6; P = .03). Four of the 52 (7.7%) cases diagnosed by hysteroscopy were stage IIIA due to cytology alone compared with 3 of the 204 (1.4%) cases diagnosed by endometrial biopsy or D&C (P = .03). CONCLUSION: Hysteroscopy appears to be associated with an increased rate of malignant cytology after controlling for confounders of stage and grade. Further, there appears to be an association between hysteroscopy and upstaging patients due to cytology alone. LEVEL OF EVIDENCE: II-2


Molecular and Cellular Endocrinology | 2009

Steroid-converting enzymes in human ovarian carcinomas

Justin C. Chura; Hyung S. Ryu; Marc Simard; Donald Poirier; Yves Tremblay; Doris C. Brooker; Charles H. Blomquist; Peter A. Argenta

Anti-estrogen therapies for treating ovarian carcinoma have had mixed outcomes suggesting some tumors may be estrogen-dependent. We assayed the activity levels of 17beta-hydroxysteroid dehydrogenase (17beta-HSD), 3beta-hydroxysteroid dehydrogenase (3beta-HSD), 3alpha-hydroxysteroid dehydrogenase (3alpha-HSD/3-KSR) and estrone sulfatase in a series of ovarian epithelial carcinomas. 17beta-HSD activity ratios with estradiol (E(2)) and testosterone (T), and inhibition by isoform-specific inhibitors were used to estimate the contributions of 17beta-HSD isoforms. Activity levels were highest for estrone sulfatase, followed, respectively by 17beta-HSD, 3alpha-HSD/3-KSR, and 3beta-HSD. E(2)/T activity ratios varied widely between samples. A 17beta-HSD type 1 inhibition pattern was observed in 23% of the samples and a type 2 pattern in 25%. E(2) formation from estrone sulfate (E(1)S) was detected in 98% (47/48) of the samples. 17beta-HSD type 1, type 2 and type 5 mRNA was detected in matched primary tumor and metastases. Evaluation of 17beta-HSD and sulfatase activity levels, activity ratios and inhibition patterns may help predict tumor response to endocrine therapy.


Gynecologic Oncology | 1979

Müllerian adenosarcoma of the uterus with rapid progression: An ultrastructural study

Takashi Okagaki; Doris C. Brooker; Leon L. Adcock; Konald A. Prem

Abstract A case of mullerian adenosarcoma arising in an 82-year-old white female with rapid successive recurrence and death was studied with electron microscopy. The primary tumor in the uterus was typical mullerian adenosarcoma described by Clement and Scully. After a simple hysterectomy, however, a recurrent tumor appeared in the vagina in 5 months. The lesions were excised, and radiation therapy was given. The patient died 13 months after the initial diagnosis, reportedly with another recurrence of the tumor. Light microscopic and electron microscopic histology of the first recurrent nodules was consistent with fibrosarcoma.


American Journal of Obstetrics and Gynecology | 1987

Infectious morbidity in gynecologic cancer

Doris C. Brooker; John E. Savage; Leo B. Twiggs; Leon L. Adcock; Konald A. Prem; Christine C. Sanders

Abstract A retrospective investigation of infectious morbidity in gynecologic oncology patients documented that 54 (11%) of 494 patients and 68 (6%) of 1204 patient admissions were complicated by a serious infection. The highest rate of infectious morbidity by admission was 21%, occurring in patients admitted for cancer of the vulva. The highest surgical infectious morbidity, 22%, occurred in patients admitted for cervical cancer. important factors in determining infection risk include multiple host factors, radical surgical procedures, factors inherent in the tumor itself, and additional irradiation and chemotherapy. These serious polymicrobial infections dictate intelligent selection of antimicrobials and appropriate monitoring to anticipate complications inherent in antimicrobial therapy. β-Lactamase induction, superinfection, nephrotoxicity, and necrotizing enterocolitis are documented problems in these patients.


Gynecologic Oncology | 1985

Immunocytochemical evidence of heterogenous origin of α-fetoprotein in immature teratoma of the ovary

David R. Burrus; Takashi Okagaki; Leo B. Twiggs; Doris C. Brooker

Abstract α-Fetoprotein (AFP) has been found to be clinically important in the management of patients with gynecologic malignancies. Serum AFP levels are used as tumor markers for ovarian tumors, namely endodermal sinus tumors (EST) and embryonal tumors. In two cases of immature teratoma of the ovary without a yolk sac component, evidence for AFP production was found in a wide variety of cells of both endodermal and ectodermal origin suggesting a heterogeneous origin of AFP. To complement this finding, a summary of the ontology of AFP along with current and potential uses of an antigenically active tumor marker are presented.


Infectious Diseases in Obstetrics & Gynecology | 1994

Infectious Morbidity After Radical Vulvectomy

Steven A. Elg; Linda F. Carson; Doris C. Brooker; Jonathan Carter; Leo B. Twiggs

Objective: This retrospective investigation describes the infectious morbidity of patients following radical vulvectomy with or without inguinal lymph node dissection. Methods: The charts of patients undergoing radical vulvectomy between January 1, 1986, and September 1, 1989, were reviewed for age, weight, cancer type, tumor stage, operative procedure(s), prophylactic antibiotic and its length of use, febrile morbidity, infection site, culture results, significant medical history, and length of use and number of drains or catheters used. Results: The study group was composed of 61 patients, 14 of whom underwent a radical vulvectomy and 47 who also had inguinal lymph node dissection performed. Twenty-nine patients (48%) had at least 1 postoperative infection. Five patients (8%) had 2 or more postoperative infections. The site and incidence of the infections were as follows: urinary tract 23%, wound 23%, lymphocyst 3%, lymphatics (lymphangitis) 5%, and bowel (pseudomembranous colitis) 3%. The most common pathogens isolated from both urine and wound sites were Pseudomonas aeruginosa, enterococcus, and Escherichia coli. A significant decrease in wound infection was demonstrated when separate incisions were made for inguinal lymph node dissection (P <0.05). The mean number of days to onset of postoperative infection for wound, urine, lymphatics, lymphocyst, and bowel were 11, 8, 57, 48, and 5, respectively. Conclusions: We conclude that the clinical appearance of post-radical vulvectomy infections is delayed when compared with other post-surgical wound infections. Second, utilizing separate inguinal surgical incisions may reduce infectious morbidity. Finally, tumor stage and type do not necessarily increase the infectious morbidity of radical vulvar surgery.


American Journal of Obstetrics and Gynecology | 1982

Placental protein 5 in gestational trophoblastic disease: localization and circulating levels.

Andrew D. Nisbet; Roy D. Bremner; Charles H.W. Horne; Doris C. Brooker; Leo B. Twiggs; Takashi Okagaki

With the use of an indirect immunoperoxidase technique (peroxidase-antiperoxidase) placental protein 5 (PP5) has been shown to be present in a high percentage of gestational trophoblastic tumors, especially the better differentiated ones. By sensitive radioimmunoassay, PP5 has further been found to be present in sera from patients with persistent gestational trophoblastic disease but not to the same frequency or extent as human chorionic gonadotropin. The only finding of clinical importance was the association in one case of high levels of PP5 and concurrent intravascular coagulation.


Infectious Diseases in Obstetrics & Gynecology | 1996

Effect of Butoconazole Nitrate 2% Vaginal Cream and Miconazole Nitrate 2% Vaginal Cream Treatments in Patients with Vulvovaginal Candidiasis

Myra Lappin; Doris C. Brooker; Carol A. Francisco; Joan Dorfman

In a multicenter, randomized, invesgtigator-blind, parallel study, 398 patients were dispensed topical butoconazole nitrate 2% cream for 3 days (n = 199) or miconazole nitrate 2% cream for 7 days (n = 199) for vaginal use. Efficacy analyses included 254 patients with culture-confirmed Candida (119 butoconazole and 135 miconazole users). Of the 398 patients issued study medication, 9 were lost to follow-up. Therefore, safety analyses included 389 patients (197 butoconazole and 192 miconazole users). Evaluations upon admission and approximately 8 and 30 days post-treatment included Candida cultures, potassium hydroxide (KOH) wet mounts, and vulvovaginal examinations, with rating of vulvovaginal signs and symptoms using a 4-point scale. Rates of clinical cure (based on sign/symptom scores), microbiologic cure (based on cultures and wet mounts), and therapeutic cure (both clinical and microbiologic cures) were assessed and were to be similar between the regimens. Therapeutic cure rates were 57.8% and 61.4% for butoconazole and miconazole, respectively. Three-day butoconazole treatment was as safe and effective as 7-day miconazole therapy in treating vulvovaginal candidiasis.


Gynecologic Oncology | 2004

Treatment and recurrence patterns in endometrial stromal sarcomas and the relation to c-kit expression

Melissa A. Geller; Peter A. Argenta; William H. Bradley; Kathryn E. Dusenbery; Doris C. Brooker; Levi S. Downs; Patricia L. Judson; Linda F. Carson; Matthew P. Boente


Archive | 1986

Device for sampling tissues and fluids from bodily cavities

Doris C. Brooker

Collaboration


Dive into the Doris C. Brooker's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Leon Adcock

University of Minnesota

View shared research outputs
Researchain Logo
Decentralizing Knowledge